SNP Genotyping in Drug Development By Dr Nicholas C. Dracopoli and Dr Kim E. Zerba SNP-based candidate gene analyses are likely to have a significant impact on predicting drug efficacy and will, undoubtedly, impact on the pharmaceutical industry's development strategies as a whole over the next few years. The human… Read More
By Dr Mark L. Nelson Less than a hundred years ago, if you developed a microbial infection your immune system couldnt handle, you died. Then came the wonder drugs, antibiotics capable of fighting the infections for you. But times have changed. Now, because of antibiotics, their use and misuse, the… Read More
Business strategy for implementation of biomarkers in drug development By Miles Flamenbaum With pharmacoproteomic biomarkers being the subject of focus among regulatory agencies as well as research institutions, many pharmaceutical companies are increasing their interest and investment in biomarker strategies. This article discusses the potential for new efficiencies and cost… Read More
From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success. Companies are… Read More
By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article… Read More
Metabolism Provides Alternative Door to Stroke Therapy By Dr Keith F. Martin and Tony Dolan Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. You know that feeling you get the day after an exaggerated attempt at physical… Read More
Proteomics In Drug Target Discovery - High-throughput meets high-efficiency By Dr Terence E. Ryan and Dr Scott D. Patterson Biochemistry is enjoying a renaissance under the guise of 'proteomics' due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and… Read More
Cell Based Assays - Seeing the light By Dr Nick Thomas High-context cell assays have the potential to take the pivotal role in the drug discovery process. So what are the features of today's leading edge cell based assay technologies and where does the future lie? We live in interesting… Read More
Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More
Data Mining in the pharmaceutical industry By Dr Robert D. Small and Herbert A. Edelstein A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not… Read More
Chemogenomics - A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts… Read More
The lab on a chip and its impact on drug discovery by Dr Simon Cowen and Dr Coulton Legge Few technology developments have had as profound an effect on society as the invention of the microchip integrated circuit in the 1960s. Since then, the power of electronic circuits has increased… Read More
The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More
New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More
Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More
Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More